Information letter to healthcare professionals regarding the medicinal product SKAYTRAN (tranexamic acid). Intravenous forms of tranexamic acid – serious, including fatal, adverse reactions due to inadvertent intrathecal administration

30.03.2026 401 review

Інформаційний лист-звернення до спеціалістів системи охорони здоров’я щодо лікарського засобу СКАЙТРАН (транексамова кислота). Внутрішньовенні форми транексамової кислоти – серйозні, включно з летальними, побічні реакції внаслідок ненавмисного інтратекального введенняPDF · 113 КБ

Завантажити

Information letter to healthcare professionals regarding the medicinal product SKAYTRAN (tranexamic acid). Intravenous forms of tranexamic acid – serious, including fatal, adverse reactions due to inadvertent intrathecal administration

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration

Information letter to healthcare professionals regarding the medicinal product SKAYTRAN (tranexamic acid). Intravenous forms of tranexamic acid – serious, including fatal, adverse reactions due to inadvertent intrathecal administration

Other materials in this section

Forum "PHARMEXPERT 2026: pharmaceutical market in the new regulatory reality"

Forum "Clinical and preclinical studies in wartime: organization and development prospects"

Pharmaceutical forum "PHARMEXPERT 2025. eCTD and pricing in Ukraine – a strategic path to integration into the international regulatory space"

PHARMEXPERT 2024. Standards. Innovations. European integration